Pharmaceuticals
CellOrigin announced treatment of the first patient with CAR-M in China and reported the second generation of CAR-M for solid tumors
HANGZHOU, China, Dec. 20, 2023 /PRNewswire/ -- Recently, a CAR-macrophage therapy product (CAR-M) SY001 from CellOrigin Biotechnology (Hangzhou) Co., Ltd. was dosed to the first patient in a hospital inChina. "A single center, single-arm, dose-escalation, exploratory clinical trial to examine t...
2023-12-21 01:00
2534
Genevoyager Unveils Gene Therapy CDMO Facility in Milestone Move
PHILADELPHIA, Dec. 20, 2023 /PRNewswire/ -- Genevoyager (Wuhan) Co., Ltd. (Genevoyager), a leading provider of one-stop CRO/CDMO services for gene therapy products, proudly announces the official opening of its Contract Development and Manufacturing Organization (CDMO) facility. This significant ...
2023-12-20 23:10
2263
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals to Showcase Ongoing Parkinson's Disease Program at the 7th Annual Sachs Associates Neuroscience Innovation Forum
ROCKVILLE, Md., Dec. 20, 2023 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS), Daewoong Pharmaceutical (KRX: 069620.KS), and NurrOn Pharmaceuticals announced their participation in the 7th Annual Sachs Associates Neuroscience Innovation Forum. The event is scheduled to take place onJanuary 7th...
2023-12-20 20:00
2582
InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs
NANJING, China, Dec. 19, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies against drug resistance, and Escugen, a clinical-stage antibody–drug conjugate (ADC) company, today announced that InxMed licensed EZWi-Fit® linker-payload pl...
2023-12-20 09:00
3413
Standigm named as a Tech Innovator in Generative AI in Drug Discovery use case
SEOUL, South Korea, Dec. 19, 2023 /PRNewswire/ -- Standigm
2023-12-19 22:00
3070
New Drug Application of Mabwell's 8MW0511 for Injection Accepted by NMPA
SHANGHAI, Dec. 19, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that the new drug application of its recombinant (yeast-secreted) human serum albumin-human granulocyte colony-stimulating factor (I) fusion protein for injec...
2023-12-19 20:00
2358
GC Biopharma Announces US FDA Approval for ALYGLO™ (Immune Globulin Intravenous, Human-stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)
YOGIN, South Korea, Dec. 17, 2023 /PRNewswire/ -- GC Biopharma Corp (006280.KS) today announces that the US Food and Drug Administration (FDA) has approved ALYGLO (immune globulin intravenous, human-stwk) 10% Liquid, formerly referred to as "GC5107," for the treatment of adult patients aged 17...
2023-12-18 09:49
2696
Caliway Closes Oversubscribed Capital Raise and Secures Over $100M to Advance CBL-514 Pivotal Phase 3 Study in Subcutaneous Fat Reduction
TAIPEI, Dec. 16, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that it has closed an oversubscribed capital raise, securing over$100M by issuing 8 million new shares. The new funding will enable Caliway to advance the clinical development of its lead pipeline CBL-514, a sma...
2023-12-16 15:47
3147
Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naïve Acute Myeloid Leukemia at ASH 2023
HONG KONG, Dec. 15, 2023 /PRNewswire/ -- Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) and treatment-naïve acute myeloid le...
2023-12-15 21:00
3026
Live from ASH 2023 | Oral Report Featuring Encouraging Data of Olverembatinib Combined with Reduced-Intensity Chemotherapy in Patients with Ph+ ALL Presented at the ASH Annual Meeting
SUZHOU, China and ROCKVILLE, Md., Dec. 14, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today thatProf. Xiaoyuan Gong of the Institute of Hemato...
2023-12-15 11:14
2971
Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)
* Nona Biosciences will receive a total of up to $53 Million in upfront and near-term payments, with the potential for milestones of up to$1.05 billion plus royalties. * Pfizer partnership expands Nona's global network of collaborations, reinforcing its commitment to providing cutting-edge te...
2023-12-15 07:30
2777
China Jo-Jo Drugstores Granted A Second Extension to Meet Nasdaq Minimum Bid Price Requirement
HANGZHOU, China, Dec. 14, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) (the "Company"), a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that on December 13, 2023, t...
2023-12-14 21:30
4923
Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for A New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs
SHANGHAI, Dec. 14, 2023 /PRNewswire/ -- The Japan-based Global Health Innovative Technology Fund (GHIT Fund) announced today that it will invest approximatelyUS$3.3 million (approximately 500 million yen[1]) in a global multicenter Phase III clinical trial project (the "Program") led by Fosun Ph...
2023-12-14 17:00
5466
Abbisko Therapeutics Announces that U.S. FDA Has Granted Fast Track Designation for Its CSF-1R Inhibitor Pimicotinib (ABSK021)
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") today announced that its CSF-1R inhibitor pimicotinib (ABSK021) has been granted the fast track designation ("FTD") by the U.S. FDA for the treatment of tenosynovial giant cell tumor ("TGCT") patients ...
2023-12-14 08:30
2875
Alebund Reports Update for AP306 (EOS789), a First-in-Class Pan-inhibitor of Sodium-dependent Phosphate Transporters, from a Completed Phase II Clinical Trial in Patients with Hyperphosphatemia on Hemodialysis
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Alebund Pharmaceuticals
2023-12-13 21:00
3241
Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Dizal today announced that the results of a phase 2 pivotal study of sunvozertinib for the treatment of platinum-pretreated non-small-cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations (exon20ins) (WU-KONG6) were published in the peer-...
2023-12-13 18:00
2565
Live from ASH 2023 | Results from Chinese Studies of Olverembatinib Presented in Oral Report at the ASH Annual Meeting for the Sixth Consecutive Year, Including Data Showing Promising Efficacy in Patients with TKI-Resistant and/or Intolerant CML-CP
SUZHOU, China and ROCKVILLE, Md., Dec. 13, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data from a randomized...
2023-12-13 16:47
3253
WuXi Vaccines Wins Second Consecutive "Best Vaccine CMO Award" at AVEA 2023
SINGAPORE, Dec. 12, 2023 /PRNewswire/ -- WuXi Vaccines, a leading global vaccine Contract Development and Manufacturing Organization (CDMO), was named "Best Vaccine CMO of the Year" for the second consecutive year at the 2023 Asia-Pacific Vaccine Excellence Awards (AVEA) ceremony. The AVEA 202...
2023-12-13 08:30
2915
CARsgen Presents Updated Research Results on Zevor-cel at 2023 ASH Annual Meeting
SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2023 American Society of Hematology ("ASH") Annual Meetin...
2023-12-12 21:50
2516
Dizal Impresses with Its Differentiated Hematological Oncology Portfolio at 2023 ASH
SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- Dizal presented compelling data from its robust portfolio of hematological oncology at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition held inSan Diego, California from December 9-12. The data showcased updated results of Dizal's ...
2023-12-12 18:00
2670
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 290 media titles]
2026-09-18 16:29Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 289 media titles]
2026-09-15 11:00
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
Tetra Pak and Soy Excellence Center Asia Host Regional Soy Food and Beverage Programme in Thailand
[Picked up by 268 media titles]
2026-09-18 11:51
Sovereign Investment Institutions Launch China-ASEAN Joint Investment Council
[Picked up by 267 media titles]
2026-09-16 09:09
Most Read
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
2026-09-15 11:00
8629
QIVIKA to Launch Smart Scope on Kickstarter, Bringing a Professional Long-Range Experience to Day-and-Night Exploration
2026-09-12 09:00
7947
Temporal Raises $550 Million in Series E Round: NYSE Content Update
2026-09-14 21:14
7041
